BIOGEN (BIOGEN) Fair Value & Analysis

IN · Market cap ₹316M

B BIOGEN BIOGEN · BSE

Price₹0.3000

Fair Value₹0.1700

Upside-43.3%

Quality34/100

Watch BIOGEN for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range ₹0.1300 – ₹0.2100

Fair value as of: Jul 5, 2026

From 18 valuation models · updated today

Share price −11.8% over the past month.

Price vs Fair Value (12 months)

12‑month range ₹0.3000 – ₹0.8657 · fair‑value band ₹0.1300 – ₹0.2100 · the ₹0.3000 price screens above the ₹0.1700 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

BIOGEN (BIOGEN) currently trades at ₹0.3000, while our model-based Fair Value estimate is ₹0.1700 — implying the stock looks roughly 43.3% overvalued today. We read business quality at 34/100 (below-average quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, BIOGEN generated revenue of ₹25.6M at a net margin of 33.6%. Revenue declined 66.2% year over year. It earns a return on equity of 0.9%. The stock trades on a trailing P/E of 30.0. Fundamentals as of Jul 5, 2026

Key figures & financial health

Revenue (TTM) ₹25.6M

Revenue growth (YoY) -66.2%

Net margin 33.6%

Return on equity 0.9%

Free cash flow ₹15.7M FY2026

P/E ratio 30.0

More key figures

Operating margin -62.1%

EPS (TTM) ₹0.0100

EPS growth (YoY) +100%

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

BIOGEN reported revenue of ₹0 in FY2026 versus ₹21.6M in FY2022. Reported net income was ₹9.6M in FY2026.

Revenue

FY22 ₹21.6M

FY23 ₹6.7M

FY24 ₹0

FY25 ₹0

FY26 ₹0

Net income

FY22 −₹86.0K

FY23 ₹4.6M

FY24 ₹19.3M

FY25 −₹2.9M

FY26 ₹9.6M

Is BIOGEN fairly valued? → Check now

Explore undervalued stocks

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is BIOGEN (BIOGEN) undervalued?

As of Jul 5, 2026, our model estimates a fair value of ₹0.1700 versus a price of ₹0.3000 — about −43% (overvalued). Model-based estimate, not financial advice.

What is the fair value of BIOGEN?

Our model-based fair value for BIOGEN is ₹0.1700 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹0.3000.

What is the quality score of BIOGEN?

BIOGEN has a Quality Score of 34/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of BIOGEN (BIOGEN)?

BIOGEN reported trailing-twelve-month revenue of about ₹25.6M (latest available figure, as of Jul 5, 2026).

What is the net profit margin of BIOGEN?

The net profit margin of BIOGEN is about 33.6%, meaning it keeps roughly 33.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.